Published in Vaccine Weekly, April 27th, 2011
Zacks' 18-page report includes detailed information about Advaxis' proprietary platform technology, the healthcare/immunotherapy market, industry peer comparisons and Advaxis' growth strategies along with their recommendations. For a free copy of the full research report, please email Zack's Equity Research email@example.com with "ADXS" as the subject. Company Notice on Zack's Equity Research Any opinions,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly